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Over the past decades the food industry has been revolutionized toward the production of
functional foods due to an increasing awareness of the consumers on the positive role of
food inwellbeing and health. By deﬁnition probiotic foodsmust contain livemicroorganisms
in adequate amounts so as to be beneﬁcial for the consumer’s health.There are numerous
probiotic foods marketed today and many probiotic strains are commercially available.
However, the question that arises is how to determine the real probiotic potential of
microorganisms.This is becoming increasingly important, as even a superﬁcial search of the
relevant literature reveals that the number of proclaimed probiotics is growing fast. While
the vast majority of probiotic microorganisms are food-related or commensal bacteria that
are often regarded as safe, probiotics from other sources are increasingly being reported
raising possible regulatory and safety issues. Potential probiotics are selected after in vitro
or in vivo assays by evaluating simple traits such as resistance to the acidic conditions of
the stomach or bile resistance, or by assessing their impact on complicated host functions
such as immune development, metabolic function or gut–brain interaction. While ﬁnal
human clinical trials are considered mandatory for communicating health beneﬁts, rather
few strains with positive studies have been able to convince legal authorities with these
health claims. Consequently, concern has been raised about the validity of the workﬂows
currently used to characterize probiotics. In this review we will present an overview of
the most common assays employed in screening for probiotics, highlighting the potential
strengths and limitations of these approaches. Furthermore, we will focus on how the
advent of omics technologies has reshaped our understanding of the biology of probiotics,
allowing the exploration of novel routes for screening and studying such microorganisms.
Keywords: probiotics, screening, mechanism, in vitro model, in vivo model, omics, molecular marker, health claim
INTRODUCTION
Probiotic research faces new challenges. Currently, there is an
increased legislative pressure, in both the EU and the USA, to
strictly limit the health communications of probiotics. While a
more strict regulation is of course not a major problem as such,
it may considerably hamper the release of new probiotic strains
and applications. This is especially worrisome, as the boost of
the metagenomics research efforts starts to pay off by creating
numerous new and interesting working hypothesis for microbiota
manipulation in maintaining and restoring health. Results of this
research, for the ﬁrst time, allow to avoid the tedious screening of
large numbers of strains and to identify potential new health pro-
moting bacteria from the comparison of population with different
health status (lean versus obese, allergic versus non-allergic, etc.).
Several new applications have been suggested already either via a
supplemented diet or via a pharmaceutical approach. Improving
Faecalibacterium prausnitzii levels has been suggested as beneﬁ-
cial for inﬂammatory bowel disease (IBD) patients (Miquel et al.,
2013), the use of Akkermansia muciniphila has recently been
patented for treating metabolic disorders (Cani et al., 2014) and
the role of dietary bioactive proteins and peptides in autism spec-
trum disorders may also result in new probiotic strains in the
market (Siniscalco and Antonucci, 2013). The legislative frame-
work today is not ready to cope with these new applications.
Approval will require a full analysis of the mechanism of action.
A full inventory of the risks will have to be determined in dif-
ferent populations, at different doses and using different delivery
modes and matrices. The research approaches presented in this
review aim to assist in this process. While many of the in vitro
models described here may seem outdated, they are still used
for cost and ethical reasons. The use of new molecular omics-
based technologies is increasing fast and it will most probably
replace traditional screening methods. Omics technologies may
also turn out to be very effective in the follow-up analysis of
probiotic candidate strains resulting from in vitro and/or in vivo
screening with current methodologies. Genome sequencing, as an
example, will allow to quickly detect and eliminate strains that
pose a potential risk, through the presence of antibiotic resis-
tance or virulence genes. The new research approaches will also
facilitate the analysis and description of functional mechanisms,
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facilitating the construction of health claim or pharmaceutical
dossiers. Another consequence of this focus on mechanisms might
be that live microorganisms will no longer be necessary, but they
will be replaced by the active ingredients or metabolites identiﬁed
as the active compound. This might cause a shift for certain appli-
cations from the food to the pharma area. However, it remains
to be shown if this shift will also result in active ingredients that
have no side effects, as it is currently expected from probiotics.
The use of the models and research strategies described in this
review, alone or in combination, may help to answer that type of
questions.
DOCUMENTING PROBIOTICS WITH IN VITRO ASSAYS
SURVIVING STRESS WITHIN THE HOST
Since the early days of probiotics research, in vitro screening of
probiotics was a preferable choice due to the simplicity and the
low cost of such approaches (Table 1). Even though some of these
tests may seem outdated they are still in use and they can be found
in recent reports. Perhaps themost important advantage of in vitro
assays is their ability to screen multiple strains simultaneously.
According to current deﬁnitions, probiotics should be viable,
even though sometimes dead microbial cells can also exert health
beneﬁts (Salminen et al., 1999). It is also recommended that pro-
biotics must be able to reach the desired body niches alive. An
initial screening of strains based on various stress tolerance assays
is of utmost importance (Upadrasta et al., 2011), especially for
non-encapsulated strains directly used in food. Hence, appropri-
ate in vitro tests have been adopted to select strains based on their
ability to survive transit through the different compartments of
the gastrointestinal tract (GIT; Joint FAO/WHO Working Group,
2002).
Survival of potential probiotic bacteria under simulated GIT
conditions has been extensively studied over the last decades and
strain-speciﬁc differences are marked throughout the literature.
Following ingestion, probiotics ﬁrst encounter the harsh condi-
tions of the stomach and they must be able to survive under
the extreme acidic conditions and the activities of the digestive
enzymes. The pH of the stomach is known to ﬂuctuate from
1–2 up to 4–5 after food consumption but most in vitro assays
have been developed to select strains that withstand extreme low
pH values. Most conventionalmethodologies include experiments
studying the survival of strains in buffers with no nutrients like
PBS or modiﬁed growth media, all adjusted to low pH. Simi-
lar experiments have not been reported for high values of pH,
mimicking the slightly alkaline conditions of the small intestine,
perhaps reﬂecting the notion that most probiotic strains are resis-
tant to alkaline conditions. Acid tolerance tests are among the
simplest tests that can be performed, allowing the routine screen-
ing of large numbers of strains. However, given the unrealistic
harsh pH conditions employed during these tests, they may result
in the loss of relatively acid sensitive probiotic candidates. For
example, acid sensitive strains could be protected from the acid
challenge of the stomach due to the buffering properties of food
vehicles or speciﬁc food ingredients. Furthermore, the strains are
most often challenged as pure cultures in either log or stationary
phase, while in reality, probiotics are delivered to the host already
stressed due to extended fermentation periods, food processing
conditions, and storage. This pre-stressed state of probiotics may
lead either to enhanced or diminished stress resistance during pas-
sage through the host, a property thatmay be species or even strain
dependent.
Except for these simpliﬁed survival tests, artiﬁcial gastric as
well as pancreatic juices have been developed to better represent
the in vivo conditions (Charteris et al., 1998). The survival in true
gastric juice obtained from human individuals has been reported
(Conway et al., 1987). Generally, synthetic gastric and pancreatic
juices include the enzymes pepsin and pancreatin, respectively,
and controlled incubation of strains in these juices have been
investigated to mimic the time spent by probiotics in the upper
and the lower GIT (Lavermicocca et al., 2008). Bile secreted in
the small intestine reduces the survival of bacteria by disrupting
the cell membrane, by inducing protein misfolding and denat-
uration and by damaging DNA. Bile salt hydrolase (BSH) is an
enzyme that hydrolyses the amino acids of conjugated bile salts
(glycine or taurine), reducing their toxicity. Tolerance to bile salt
concentrations between 0.15 and 0.5% has been recommended
for probiotics, which is in the range of the physiological con-
centrations met in the GIT (Gorbach and Goldin, 1992). Again,
bile tolerance assays may be easy to perform, but they may not
particularly facilitate the reliable selection of probiotics, for sev-
eral reasons. For example, in most cases strains are separately
studied for acid or bile tolerance, despite the fact that these two
stresses are actually sequential during passage through the GIT,
increasing the stress pressure. The use of non-human bile may
also raise some questions, as bovine or porcine bile do not have
the same impact on microorganisms as human bile (Begley et al.,
2005).
The need for more elaborate in vitro assays for testing the
fate of probiotic strains in the GIT led to the development of
several GIT simulators. More precisely, a multi-compartmental
dynamic computer-controlled model simulating the stomach
and the small intestine (Minekus et al., 1999) has been used
to quantify the survival of lactic acid bacteria (LAB) and the
data obtained correlated well with those obtained from human
subjects (Marteau et al., 1997). In other cases, in vitro systems
reproduce not only the conditions of the stomach and the small
intestine but also those occurring in the oral cavity using an
oro-gastric-intestinal (OGI) system (Bove et al., 2012). The sim-
ulator of the human intestinal microbial ecosystem (SHIME) was
developed by inoculating human fecal material in a fermenter-
based simulator to establish a GIT-like microbial population
(Molly et al., 1994). Experiments with SHIME revealed sim-
ilar survival rates of microorganisms to those obtained with
in vivo tests (Cook et al., 2012). A modiﬁcation of the SHIME
system involved the incorporation of a mucosal environment
in the SHIME model, resulting in a more representative col-
onization ability for the test strains (Van den Abbeele et al.,
2012). Another system that relied on two separate fermenters
was designed to better simulate the physiological events of inges-
tion and digestion in the upper GIT. Using this system, it was
possible to investigate the survival of probiotics through more
realistic pH values, i.e., those that prevail prior, during and
after a meal (Mainville et al., 2005). Obviously, GIT simulators
offer many advantages over independent in vitro tests and the
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selection of probiotic strains using these systems may be more
reliable. However, such simulators do not allow rapid screening of
multiple strains and they may be relatively expensive to maintain
and operate. Today advancements in encapsulation technology
allow the targeted delivery of probiotic strains to different com-
partments of the GIT in an active state irrespectively of their stress
robustness.
SAFETY ASSAYS
Another important aspect in selecting probiotic strains is their
safety status. While in Europe QPS regulation has identiﬁed the
microorganisms that can be safely used in foods, there might be
some safety aspects that may need to be evaluated before commer-
cial probiotic cultures are put on the market (Joint FAO/WHO
Working Group, 2002). Laboratory tests applied for the safety
evaluation of probiotic cultures include in vitro assays examining
different intrinsic properties of the strains. Initially, the min-
imum inhibitory concentrations (MICs) for the most relevant
antibiotics is usually determined and evaluated using protocols
given by EFSA (2008). The microdilution-broth test performed
on 96-well microplates (Argyri et al., 2013), the disk-diffusing
method (Pisano et al., 2014) and ready-to-use commercial kits
(Delgado et al., 2007) have been applied to specify MIC values of
known antibiotics for potential probiotic strains in many cases.
Hemolytic activity is also examined (Joint FAO/WHO Working
Group, 2002). Clear zones of hydrolysis, partial hydrolysis or no
reaction around the streaking of strains on blood agar plates indi-
cate the hemolytic ability of probiotics (Pisano et al., 2014). In vitro
tests of pathogenic traits concern the ability of bacteria to bind
to mammalian cells such as platelets, which is coupled with their
binding toﬁbronectin, ﬁbrinogen and collagen (Harty et al., 1994).
The production of certain enzymes (e.g., glycosidases, proteases
and gelatinases) is also perceived as a potential pathogenicity trait
(Oakey et al., 1995; Bernardeau et al., 2006). Strains should be
testedwith appropriate in vitro assays for the production of known
human toxins (e.g., cytolysins; Tan et al., 2013). Biogenic amines
are usually generated by decarboxylation of the corresponding
amino acids through substrate-speciﬁc decarboxylases of bacte-
ria. Assays performed on solid media are based on the pH change
of the medium after bacterial growth, corresponding to positive
decarboxylase activity (Bover-Cid and Holzapfel, 1999). Quan-
titative analysis of biogenic amines is generally accomplished by
chromatography using amino acid analyzers (Halász et al., 1994).
In vitro safety tests are generally very useful to identify and exclude
clean-cut cases of pathogenic strains from being used as probi-
otics. For example, a hemolytic or a toxin producing strain can be
easily identiﬁed and excluded from further analysis. The problem
with the in vitro safety assays concerns the identiﬁcation of false
negative strains. A virulence trait may be simply non-active under
the speciﬁc conditions of the assay and thus remain undetectable
(e.g., a toxin that may be down-regulated in vitro). Virulence is a
complex phenomenon that sometimes needs an active interaction
with the host to be triggered and for this reason in vivo models
may be more appropriate. The screening of the bacterial genome
for the presence of virulence and resistance genes (see below) is
also a way to predict the possibility of non-expressed safety risk
factors.
COLONIZATION OF THE HOST AS A PREREQUISITE TO EXERT CERTAIN
HEALTH BENEFITS
Although research in the probiotic area has considerably pro-
gressed the last decades, the correlation of speciﬁc cultures with
speciﬁc health claims is still ambiguous. In a relatively limited
number of cases speciﬁc in vitro assays have been devised to inves-
tigate the protective or therapeutic role of probiotic candidates
against certain diseases. The simplest application is the competi-
tion of the probiotics with potential pathogens for resources and
space in the GIT. Adherence to mucus and epithelial cells is still
considered a controversial topic in probiotics research. On the
one hand it is a desirable probiotic trait, as it facilitates coloniza-
tion of the host and antagonism against pathogens, but on the
other hand it is considered as a risk for translocation. The latter
might be especially important in highly sensitive populations of
immune depressed patients where probiotic applications are often
considered (Sanders et al., 2010).
The hydrophobicity phenotype of bacterial cell surface is
related to their adhesive capacity and colonization of the gut
(Ouwehand et al., 1999). Generally, cell surface hydrophobic-
ity is determined according to the capacity of the bacteria to
partition into hydrocarbons (i.e., hexadecane, xylene, toluene;
Kaushik et al., 2009; Jena et al., 2013), thus, reﬂecting the non-
speciﬁc adhesion capability related to cell surface characteristics
(García-Cayuela et al., 2014). Controversial results of hydropho-
bicity studies show that this feature might be questionable (Vin-
derola et al., 2004). In general, assessing the adhesive capacity
of probiotic strains based on surface hydrophobicity is rather
outdated.
Adhesion tests of probiotics to human intestinal mucus
obtained from infants or healthy human feces have been per-
formed (Kirjavainen et al., 1998; Ferreira et al., 2011). Moreover,
high-throughput screening methods based on immobilized com-
mercially available mucin have also been reported (Laparra and
Sanz, 2009). Mucins are large glycoproteins that fortify intesti-
nal mucosal surfaces forming a protective shield for the epithelial
cells against harmful environmental conditions. Glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) expressed on the bacterial
cell surface aidbinding tohumancolonicmucin and the evaluation
of this enzymatic activity has been reported as a simple screening
method (Kinoshita et al., 2013). Alternatively, other studies have
focused on the ability of probiotic bacteria to form cellular aggre-
gates via self-aggregation (auto-aggregation; Del Re et al., 2000)
by measuring absorbance of bacterial suspensions that are left
standing for certain time intervals (Collado et al., 2008). Auto-
aggregation capacity of LAB is correlated to their adhesion to
different kind of host cells (Malik et al., 2013), and it is considered
as a desirable characteristic for preliminary probiotic screening
(Bao et al., 2010; Botta et al., 2014). Intestinal epithelial cell (IEC)
lines are often presumed to better represent conditions in the tis-
sues of the GIT (i.e., adhesion ability and colonization of probiotic
strains). Several studies have been conducted using human epithe-
lial cell lines (like HT-29, HT-29MTX, and Caco-2) to screen the
adhesion of probiotic strains (Muller et al., 2009). In general, the
in vitro testing of the adhesion potential is considered experimen-
tally difﬁcult. Reproducibility issues have been observed among
laboratories due to the use of different variants of a given cell line
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and of high background levels (Kirjavainen et al., 1998). These
tests can only yield rough indications of a strain’s potential to
adhere in vivo. Additionally, resected intestinal tissue fragments
have been used unprocessed or immobilized on microtitre plates
for adhesion assays (Vesterlund et al., 2005). Finally, the whole tis-
sue models consisting of the epithelial tissue with the mucus layer
in the presence of commensal microbiota may allow the assess-
ment of more complex adhesive interactions between probiotics
and the host (Tassell and Miller, 2011).
Several molecules that are actively aiding the binding to host’s
cells have been identiﬁed. The problem with the in vitro assays
is their inability to recapture the actual conditions prevailing in
the GIT. In most cases adhesion is studied for single strains thus
in the absence of any additional microbiota that would mimic
the gut microbiome. This is a very important drawback for most
assays, since there is ﬁerce competition for adhesion sites among
the different microbes in vivo. The use of cancer cells is also a bit
controversial since their extracellular matrix and surface proper-
tiesmaydiffer signiﬁcantly fromthat of healthy IECs. Nevertheless,
strains shown to adhere with high efﬁciency to human cells in vitro
usually behaves in a similar manner in vivo.
ANTIMICROBIAL ASSAYS
Another desired attribute is the production of antimicrobial
compounds by probiotics. Perturbation of the GIT microbiome
plays an important role in the pathophysiology of common gas-
trointestinal infectious diseases. Researchers have proposed that
probiotics may prevent gastrointestinal disorders by maintaining
homeostasis of the gut microbiome or by competitively inhibiting
the growth of pathogens (Hickson, 2011). Selection of probiotic
bacteria active against infectious diarrhea attributed to viruses
(e.g., rotavirus and norovirus; Al Kassaa et al., 2014) or bacte-
ria (e.g., Escherichia coli, Salmonella and Campylobacter sp.) or
to Clostridium difﬁcile infection (Parkes et al., 2009), is usually
based on antimicrobial properties of probiotic strains. This is
also the case for antibiotic-associated diarrhea (Cresci et al., 2013)
and Helicobacter pylori infection (Chenoll et al., 2011), as well as
for infections related to sites of the human body other than the
GIT, such as the oral cavity (Haukioja, 2010), the upper respira-
tory tract (Kechaou et al., 2013), and the urogenital system (Strus
et al., 2005). In addition to the production of known antimicro-
bial metabolites such as organic acids, probiotic bacteria may also
produce specialized inhibitory agents, like bacteriocins. Target
strains commonly include both Gram positive and Gram nega-
tive bacteria, as well as fungal strains, comprising of not only
pathogenic bacteria but also strains representative of the predom-
inant human GIT microbiota (Gagnon et al., 2011). In general,
antagonistic activity is evaluated in vitro using simple inhibition
tests performed on solid media. More precisely, the agar spot test
(Jacobsen et al., 1999), the paper-disk diffusion assay (Guo et al.,
2010), and the well diffusion assay (Tagg and McGiven, 1971)
have been extensively used asmethods for evaluating antimicrobial
activity. Moreover, inhibitory effects of probiotic culture ﬁltrates
assessed by an automated turbidometric assay that monitors the
ability of the indicator bacteria to grow has also been reported
(Lahteinen et al., 2010). In some cases, bioluminescent indica-
tor strains were also used to investigate the possible production
of antimicrobial compounds from probiotic bacteria (Lahtinen
et al., 2007). Assays as the cross-streak and the radial streak meth-
ods are comparatively more efﬁcient in terms of examining the
inhibitory properties of intact probiotic cells and not only prop-
erties attributed to their producing metabolites (Coman et al.,
2014).
Antimicrobial ability of probiotics refers not only to the pro-
duction of antimicrobial compounds or acids that affect luminal
pH (Suardi et al., 2013), but also the competitive exclusion of
pathogens. Probiotics may compete with pathogens for bind-
ing sites on the surface of the GIT. The in vitro adhesion assays
mentioned earlier can be used to assess the binding competition
between probiotic and pathogenic strains. In this context, bacte-
rial aggregation between genetically distinct cells (co-aggregation)
is of considerable importance. Thus, protective properties of pro-
biotics against pathogen infections can also be evaluated through
co-aggregation assays based not only on simple absorbance mea-
surements but also on radiolabelling and ﬂuorescence detection
(Collado et al., 2007).
Antimicrobial properties of probiotics are also correlated with
the enhancement of the intestinal barrier function (Mennigen and
Bruewer, 2009). Barrier properties can be investigated by measur-
ing trans-epithelial electrical resistance (TEER) before and after
apical exposure of IEC lines to bacteria (Zyrek et al., 2007). Pro-
motion of tight junction integrity is known to block paracellular
transport of pathogenic bacteria. Alterations of tight junction
proteins are examined in vitro either by immunoﬂuorescence
using speciﬁc antibodies (Ewaschuk et al., 2008), or by evalu-
ating the capacity of probiotics to alter tight junctional protein
phosphorylation (Resta-Lenert and Barrett, 2003).
Once more, the in vitro production of antimicrobial substances
alone cannot provide us with important information about the
probiotics application in vivo. We cannot know if the selected
strain will be able to be incorporated in the microbiome and
whether the conditions prevailing in the GIT will allow it to
produce its antimicrobial(s) compounds at sufﬁcient amounts to
have an effect. Usually, probiotic strains produce more than one
antimicrobial substance that may act synergistically, increasing
the spectrum of targeted microorganisms. This property may be
desirable as long as this antimicrobial spectrum is restricted to
pathogenic microorganisms but it cannot be excluded that it will
not affect the normal microbiota of the gut as well. Similarly to
other tests, antimicrobial assays may lead to false negatives, i.e.,
strains that are capable of biosynthesizing antimicrobial(s) but
they do not produce it under the in vitro conditions employed.
In addition, antimicrobials of probiotics are generally perceived
as safe and in most cases the toxicity to host’s cells is rarely
investigated. There is a clear need for more elaborate assays
that would better represent the complex interactions between
the probiotics and the host microbiome to understand the con-
sequences of the in situ production of antimicrobials by the
former.
IMMUNOMODULATION
Modulation of host immunity is one of the most commonly pro-
posed health beneﬁts attributed to the consumption of probiotics.
Probiotic selection that is correlated to the protection against
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microbial pathogens has been associated with the stimulation of
antibody secretion, as well as cell-mediated immune responses
(Cross, 2002). Evaluation of the bacterial translocation in the
GIT can be used to screen potential probiotic strains, consid-
ering that some strains may be capable of triggering dendritic
cells (DCs) or M cells from the Peyer’s patches and thereby man-
age to cross the epithelium (Corthesy et al., 2007). In most of
the in vitro experiments, researchers have attempted to reconcile
the mechanisms underlying the complex and dynamic immune
interactions of the gut by using co-culture models (Cencic and
Langerholc, 2010) or 3D models (Borchers et al., 2009). The use of
three componentmodels (epithelia, immune cells andmicrobiota)
closely mimics the in vivo situation (Fontana et al., 2013). In addi-
tion, several reports highlight the complex interaction between the
host immune system and different bacterial compounds, includ-
ing chromosomal DNA, cell wall components such as lipoteichoic
acids and peptidoglycan, as well as soluble metabolites (Corthesy
et al., 2007). In these assays, cytokines like IL-5, IL-10, IL-12b, IL-
17a, IFN-γ, TNF-α, and TGF-β, as well as the levels of the secretory
immunoglobulin typeA (sIgA) are used to assess stimulationof the
immune response and the inﬂammation status (Miettinen et al.,
1998; Steinberg et al., 2014).
IBD covers a family of chronic diseases affecting the GIT, hav-
ing as most common forms Crohn’s disease (CD) and ulcerative
colitis (UC). Propitious functions of the probiotics for allevia-
tion of IBD symptoms involve the ability to restore biodiversity
within the microbiota, the antagonism against pathogens, the
improvement of mucus production, the stimulation of epithelial
proliferation, the modulation of intestinal permeability and the
mediation of pro-inﬂammatory effects (Scaldaferri et al., 2013).
In vitro models for probiotic selection in IBD research are alike to
thosementioned previously. Speciﬁcally, assays that investigate the
antimicrobial activity against microbes that help alter microbial
biodiversity within the gut, the regulation of epithelial tight junc-
tions and the induction of an anti-inﬂammatory cytokine proﬁle
(high IL-10/IL-12 ratio) from immune cells, are commonly used
(McKay et al., 1997; Foligne et al., 2007).
Allergy is a complex immune response to environmental or
food antigenic stimuli and it is mostly correlated with the hyper-
sensitivity reaction mediated by the interaction of immune cells
coated with allergen-speciﬁc IgE that requires the involvement
of T-cells with a Th2-skewed cytokine proﬁle (Furrie, 2005).
Th2-skewed immune cells have extensively been studied to select
probiotic strains that exert certain immune-stimulating proper-
ties for further in vivo use (Fujiwara et al., 2004). Alleviation of
allergic symptoms has also been correlated to the induction of the
immunosuppressive cytokines IL-10 and TGF-β or the reduction
of T-cell proliferation (Smits et al., 2005). The β-hexosaminidase
release assay helps to identify potential anti-allergic probiotics,
since the secretion of this molecule corresponds to a hallmark of
allergic reactions resulting from exposure of mast cells to antigens
(Kim et al., 2013).
Disturbance in the balance of the normal microbiome in differ-
ent body niches can lead to inﬂammation. Probiotics known for
their anti-inﬂammatory cytokine proﬁle from immune cells can
be efﬁcacious in moderating this inﬂammation as in the case of
caries and periodontal disease or of functional digestive disorders
such as the irritable bowel syndrome (IBS; Krasse et al., 2006; Gill
et al., 2009).
While we found the measurement of cytokine levels produced
by peripheral blood mononuclear cells (PBMCs) upon stimula-
tion with probiotics to be a reliable and reproducible technique
to identify strains with potential pro- or anti-inﬂammatory prop-
erties, the in vivo relevance can be questioned as the test involves
only one type of immune cells and ignores the complexity of the
in vivo communication between different cell types. The model is
also blind for the differences between the innate and the adaptive
immune system. Moreover, the model does not reﬂect differ-
ences of the immune system in relation to certain pathologies.
Despite these limitations, experiments with PBMCs are of major
interest, as they will allow to quantitatively classify strains and
select strains with opposite proﬁles, e.g., for further mechanistic
investigation.
CARDIOVASCULAR DISEASES (CVDs)
Several reports have demonstrated that manipulating the gut
microbiome with probiotics may affect host metabolism and ulti-
mately reduce the risk for CVDs. Increased bacterial BSH activity
in probiotic strains can result in decreased body weight gain, lower
levels of plasma cholesterol, and liver triglycerides (Cani and Van
Hul, 2015). Bile salt hydrolyzing activity can be evaluated qual-
itatively by the plate assay method using taurodeoxycholic acid
(TDCA) sodium salt (Dashkevicz and Feighner, 1989), and quan-
titatively by high-performance liquid chromatography (Smet et al.,
1994). The deconjugation of bile salts can lead to secretion of
cholesterol and lipids via the fecal route (Zheng et al., 2013). An
in vitro assay for the conversion of cholesterol to coprostanol
by the action of bacterial cholesterol reductase has also been
described (Lye et al., 2010). In relation to cholesterol, coprostanol
is less absorbed in the intestine and it can be easier removed
with feces. Furthermore, the assimilation of cholesterol present
in the growth media by probiotic strains has been tested in vitro
(Tomaro-Duchesneau et al., 2014).
Probiotic strains and metabolic by-products potentially con-
fer beneﬁts to the heart by the prevention and therapy of heart
syndromes, as well as by lowering serum cholesterol (Ebel et al.,
2014). The ACE enzyme has a key role in the rennin–angiotensin
system which controls the arterial blood pressure and the equilib-
rium of water and salt in the body. The hydrolysis of angiotensin
I to angiotensin II, which is a strong vasoconstrictor agent from
the ACE enzyme, can lead to an increase in blood pressure. Dur-
ing proteolysis of extracellular proteins like casein, peptides are
being released that may inhibit ACE-I activity which is used as a
screening tool (Papadimitriou et al., 2007).
There are several lines of evidence that support the positive
implication of probiotics to the prevention of cardiovascular dis-
eases (Ebel et al., 2014). However, the actual mechanisms involved
are not well understood and thus the in vitro assays available for
this type of health claims are relatively restricted. Improving the
barrier is generally considered an effective way to decrease basic
physiological inﬂammation of e.g., adipose tissue, contributing to
a reduced risk for the development of overweight and metabolic
syndrome and therefore positively affecting CVD risks. A general
comment can be made regarding the currently available assays for
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cholesterol absorption or its conversion to coprostanol. The length
of these in vitro test protocols (often more than 20 h) may not
match the in vivo time window for the absorption of cholesterol
in the intestine after emulsiﬁcation.
ANTICANCER
The gut microbiota is considered to be related to the risk of can-
cer and it has been suggested that consumption of probiotics may
decrease this risk. The important role of probiotics in retarding
carcinogenesis is attributed to their ability to inﬂuence metabolic,
immunologic, and protective functions in the body (Wollowski
et al., 2001). Antimutagenic activities of probiotics have been eval-
uated by theAmes test (Burns and Rowland, 2004). Probiotics also
exerted an antigenotoxic activity related to decreasedDNAdamage
of colon cells treated with carcinogens as evaluated by the “comet
assay” (Pool-Zobel et al., 1996). The nitrosamine degrading assay
(Duangjitcharoen et al., 2014) and the evaluation of the antioxi-
dant properties of bacterial samples, i.e., intact cells and cell-free
culture supernatants, are used for the detection of potential pro-
biotics against cancer (Amaretti et al., 2013). Bacterial cell-free
culture supernatants of probiotic strains have also been tested for
preventing colon cancer cell invasion in vitro (Choi et al., 2006).
Strains showing in vitro inhibitory activity on tumor cell prolif-
eration, induction of apoptotic cell death, and ability of cellular
sphingolipidic metabolism, have been recognized as promising
candidates for cancer prevention (Castro et al., 2010). Moreover,
a possible mechanism of anti-carcinogenic properties of probi-
otic strains involves the physical binding by the bacterial cell of
the mutagenic compounds, such as heterocyclic amines (HCAs).
Speciﬁcally, bacterial strains that are able to sequester HCAs could
decrease their absorption by the human intestine via their elimina-
tion through feces carryover (Faridnia et al., 2010). Furthermore,
in vitro removal of toxins and toxicmetals present in aqueous solu-
tions or in drinking water has been studied for selected probiotics
(Halttunen et al., 2007; Nybom et al., 2008). Also, luminal short
chain fatty acids (SCFAs), produced in the colonic lumen during
bacterial fermentation, are known anti-carcinogenic agents within
the gut (Commane et al., 2005). In the past, the inﬂuence of pro-
biotic bacteria on the production of SCFAs by fecal bacteria was
studied in vitro using batch-culture and continuous-culture tech-
niques (Sakata et al., 2003). In vitro GITmodels as described above
can also be used.
The aforementioned in vitro assays for anticancer properties
of probiotic bacteria provide minimal information about the
actual in vivo efﬁcacy. On one hand, probiotic bacteria showing
antimutagenic and/or antigenotoxic activities may exert general-
ized prophylaxis against gut related cancers. On the other hand,
probiotics producing SCFAsmay have amore direct effect by selec-
tively killing cancer cells as it has been demonstrated for propionic
acid bacteria (Cousin et al., 2012) or by assisting in the renewal of
the colonic epithelia by butyric acid (Mariadason et al., 1999) or
its effect on histone deacytelase (Boffa et al., 1992).
Generally, the existing in vitro assays are not sufﬁcient to truly
screen probiotics for anticancer properties and thus in vivo assays
will be necessary. In any case, the idea of using bacteria (some
of which are known probiotics, like biﬁdobacteria) in the treat-
ment of cancer is gaining momentum (Chong, 2014). As the
mechanisms of cancer prevention and therapy become clearer,
new and more elaborate in vitro assays may be developed in the
future.
ADDITIONAL HEALTH BENEFITS
There are several additional health beneﬁts that have been
attributed to probiotics. Lactose intolerance, attributed to an
insufﬁcient amount of lactase in the small intestine to early
hydrolyze lactose, is an important problem when consuming milk
or lactose containing foods (Kim and Gilliland, 1983; Céspedes
et al., 2013). Dairy products containing probiotic bacteria could
aid the digestion of lactose by their β-galactosidase enzyme when
crossing or colonizing the gut. Screening for β-galactosidase activ-
ity in potential probiotics is assessed through the hydrolysis of the
o-nitrophenol-β-galactopyranoside (Hughes and Hoover, 1995).
Other nutritional effects of probiotics relate to the production
of vitamins. Theyplay amajor role inhelpinghumans tomeet their
needs for these essential nutrients (Eck and Friel, 2013). In vitro
studies have documented the capacity of some probiotic strains
to synthesize vitamin K, folic acid, vitamin B2, and B12 (Pompei
et al., 2007).
Probiotics may also have a protective role against oxidative
stress in the host (Songisepp et al., 2005). Oxidative stress hasmany
physiological consequences to the host including aging, carcino-
genesis, etc. Evaluation of the antioxidative activity of probiotics is
usually assessed by the linolenic acid test (LA-test; Kullisaar et al.,
2002).
Furthermore, the role of oxalate-degradingbacteria in the treat-
ment of kidney stone disease is of particular interest (Abratt and
Reid, 2010). Identiﬁcation of potential probiotic strains through
the evaluation of oxalate degradation by pure cultures has been
reported (Campieri et al., 2001).
Lastly, volatile sulfur compounds (VSCs) produced by oral bac-
teria can cause halitosis. An in vitro test was developed by Kang
et al. (2006) in which the inﬂuence of LAB on VSC production by
Fusobacterium nucleatum could be assessed. Interestingly, inhibi-
tion of VSC production was related to co-aggregation of the LAB
strains with F. nucleatum as well as the production of H2O2 by the
former.
FUTURE PERSPECTIVES FOR THE USE OF IN VITRO TESTS IN PROBIOTIC
RESEARCH
There are several in vitro assays that are being employed in an
attempt to predetermine or document probiotic properties in rela-
tion to health claims. Even though such assays are useful to screen
probiotic candidates they exhibit variable effectiveness. Regula-
tory authorities have attempted the standardization of the in vitro
assays by publishing detailed protocols and directives. Unfortu-
nately, even a superﬁcial examination of the literature reveals that
in vitro tests are being performed in a rather arbitrarymanner. This
makes it difﬁcult to compare ﬁndings between different studies.
Reproducibility issues have also been reported, making it difﬁcult
to rely solely on the outcomes of in vitro tests for the selection of
probiotic strains. Apparently, in vivo assays may be more appro-
priate but in most cases they cannot be used for high throughput
screening due to the increased cost and for ethical reasons. There-
fore, in vitro screening is and will be an indispensable part of the
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discovery of new probiotics. More research is needed to improve
and standardize the available experimental protocols aiming at
improving reproducibility and decreasing the percentages of false
positively or negatively identiﬁed strains with probiotic potential.
Additionally, novel methods might need to be developed that will
extend the health-promoting properties currently assessed with
in vitro tests.
DISCOVERING PROBIOTIC MICROORGANISMS: IN VIVO
APPROACHES
THE RIGHT MODEL FOR THE RIGHT PURPOSE
The use of in vivo approaches to explore probiotic potential
resulted in the description of a huge diversity of biological mod-
els of various complexity, ranging from simple multicellular
organisms such as worms and invertebrates over sophisticated
knock-out (KO) models in rodents to human clinical trials in dif-
ferent types of the population (Figure 1; Table 2). While all these
models can teach us something, they also represent certain dis-
advantages and integrating results from different models remains
difﬁcult. Therefore, while ﬁnal assessment of probiotic function-
ality should ideally be performed directly in the target population
(general population or a subgroup with a given condition; Rijkers
et al., 2010), the pre-selection of strains to be included in these
expensive clinical trials might need to be made using appropriate
in vivo models.
Indeed, while rudimentary models such as Caenorhabditis ele-
gans, or Drosophila exhibit obvious beneﬁts for (large) screening
purposes, they are also not devoid of relevance in deciphering
more universal signaling pathways, even related to mammalian
innate immunity, as shown by the work of the Nobel prize winner
Hoffmann and his team (Vogel, 2012). C. elegans was successfully
applied to establish the anti-infective, antioxidative and lifespan
extending impact of lactobacilli (Wang et al., 2011; Grompone
et al., 2012). The prototype worm is currently proposed to screen
probiotics (Park et al., 2014), or to establish antitumor activ-
ity (Fasseas et al., 2013). In a similar way, the ﬂy is useful to
explore metabolic, immune and antioxidant effects of the Lac-
tobacillus-host mutualism (Jones et al., 2013; Matos and Leulier,
2014).
Quite recently, the zebraﬁsh (Danio rerio) has garnered intense
interest as a human disease model (Lieschke and Currie, 2007)
due to its many advantages as an experimental vertebrate. It now
appears that the zebraﬁsh can be used for high-throughput screen-
ing (e.g., of drug libraries) in the discovery process of promising
new therapeutics (Lessman, 2011). The latter was successfully
developed for probiotics, showing that probiotic administration
may enhance the zebraﬁsh welfare by modulating the innate
immune response and improving hepatic stress tolerance, involv-
ing stress and apoptosis genes, and genes from the innate immune
system(Gioacchini et al., 2014; Rieu et al., 2014). Of note, zebraﬁsh
can also partly mimic characteristics of IBDs when larvae are sub-
jected to chemicals such as trinitrobenzene sulfonic acid (TNBS;
Fleming et al., 2010) or when encountering unfavorable condi-
tions, including dysbiosis of the intestinal microbiota (He et al.,
2013). Modiﬁcations include colitis susceptibility genes likeNOD1
and NOD2 (Oehlers et al., 2011), enabling the routine evaluation
of anti-inﬂammatory compounds.
RODENTS AS THE NECESSARY COMPROMISE
The small animal models mentioned above clearly meet the needs
for cost effective and public-acceptable screening but are still
far away from an integrated mammalian physiology. Therefore
more pertinent experimental models are required for the evalua-
tion of probiotic functionality, allowing to study various dynamic
states and when addressing speciﬁc diseases with multifactorial
origins.
Accuracy of the results of animal models is not always in per-
fect accordance with human outcomes and may sometimes appear
FIGURE 1 | Progressive complexity of in vivo models used to support probiotic health effects.
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Table 2 | Advantages of using small animals/rodent models for probiotic research support.
Functionality Possible intervention/improvement Representative references
Physiological relevance for humans
(Immune system, neuroendocrinological system)
Transgenic mice (knock-out/ knock-in) Helm and Burks (2002)
Closely related innate and adaptive immunity
(PRRs and signaling cascades, secretory Ig, T and B
cells, DCs, etc.)
Tissue-speciﬁc knock-out Sodhi et al. (2012)
Sharing of similar immune response types
(Th1, Th2, Th17, Treg cells and cytokine responses)
Conditional knock-out Sodhi et al. (2012)
Hosting complex microbiota (gut, vagina, lung, skin) Humanized mice Martin et al. (2008)
Axenic mice Verdu and Collins (2004)
Monocolonized mice Eaton et al. (2011)
Microbiota transplantation Le Roy et al. (2013)
Co-housing Henao-Mejia et al. (2012)
Selective antibiotic treatment Ichinohe et al. (2011), Viaud et al. (2013)
Responsiveness to many infectious, immune and other
disorders
Allergy, inﬂammation (asthma, COPD, IBD, etc.) Kim et al. (2014)
Bacteria, virus, fungi and parasites pathogens Alak et al. (1997), Villena et al. (2011),
Collins et al. (2014), Kikuchi et al. (2014)
Neurologic disorders (EAE, visceral pain) Eutamene et al. (2007), Rousseaux
et al. (2007), Kwon et al. (2013)
Stress, cognitive functions Gilbert et al. (2013), Hsiao et al. (2013)
problematic as it was for example recently stated: “Inﬂammatory
ﬁndings on species extrapolations: humans are deﬁnitely no 70-kg
mice” (Leist and Hartung, 2013; Seok et al., 2013). Whether ani-
mals can be used to predict human response to drugs, chemicals
or foods (including probiotics) is apparently a contentious issue.
While some will promote a ban on animal experimentation which
lacks scientiﬁc evidence for human predictivity (Knight, 2007), the
relevance of e.g., mice disease models for humans has been judged
rather positively during a dedicated European Commission work-
shop held in the UK1. However, a certain level of criticism on the
relevance of animal models does apply. Shanks et al. (2009) illus-
trate with numerous examples their importance, or lack thereof, in
the different steps of the complete research process. They discuss,
as an example, the bioavailability differences between primates,
rodents, and dogs. When speciﬁcally considering probiotic inter-
actions with the host microbiota, a deeper comprehension of the
symbiosis between animals and bacteria is key to understanding
the complex biology of environmental, genetic and microbiome
interactions in relation to human health and disease evolution.
Kostic et al. (2013) reviewed how model systems are inﬂuenc-
ing the current understanding of host–microbiota interactions by
exploring recent human microbiome studies. They conclude that
experimental model systems, including mice, ﬁsh, insects, and the
Hawaiian bobtail squid, continue to provide critical insight into
how host–microbiota homeostasis is constructed and maintained.
Taking also into account the dynamics of the human microbiome
through human life stages, predictive value of simple models may
1http://ec.europa.eu/research/health/pdf/summary-report-25082010_en.pdf
indeed have its limits, but their use may be crucial in under-
standing mechanisms of interactions and regulation of metabolic,
physiological, and immunological activities.
Effective use of rodent models will depend on extreme stan-
dardization, including the microbiota composition. Relevance for
the human situation needs to be considered at any time, as e.g.,
many bacterial species which are commensal for humans can be
pathogenic in mice and vice versa (Baker, 1998; Pan et al., 2014).
Despite all these possible drawbacks, small animals such as rats and
mice will inevitably be continued to be used as models to address
numerous research questions related to probiotics, including the
evaluation of immune and metabolic responsiveness, regula-
tory processes or neuro-endocrinological and nutritional aspects,
which all play important roles in the complex microbiota–host
relationships. Moreover, small animals permit to mimic speciﬁc
diseases, e.g., by using geneticallymodiﬁed specimens (conditional
and tissues-speciﬁc knock-in/knock-out mutants, Table 2) or spe-
ciﬁc chemicals (e.g., TNBS to induce intestinal inﬂammation) and
infectious challenges, whilemanipulation of themicrobiota allows
to question the role of (a) speciﬁc microorganism(s) (Table 2).
FITTING ETHICS AND LEGISLATION
Controversy on animal experimentation has always been high.
Researchers in need of animal models have to cope with ethical
and legal considerations, as well as with a public opinion that
often is not fully aware of the economic and societal importance
of the research envisaged, nor of the regulatory context which also
limits the unethical use of animal suffering. Researchers are also
actively required to ensure that animal models (i) are scientiﬁcally
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(and statistically) validated (ii) cannot be replaced by in vitro
alternatives and (iii) minimize animal suffering by limiting the
number of animals and the length of the experimentation to what
is statistically required. Research strategies and methods should be
challenged continuously and reviewed objectively with respect to
the 3Rs rule established more than 50 years ago, i.e., use oppor-
tunities to replace, reduce and reﬁne (Russel and Burch, 1959).
In addition to the proper management of pain by analgesia and
anesthesia, welfare accommodations improved tremendously fol-
lowing the most recent US and EU animal housing guidelines.
Mice and rats should be allowed sufﬁcient space of adequate com-
plexity, allowing to express a wide range of normal behaviors, and
providing enrichment possibilities to promote physical exercise,
foraging, manipulative and cognitive activities, whenever possible
(Richmond, 2000).
In this review we do not focus on the use of large mam-
mals (pigs, dogs, or monkeys) as these are not widely available
and ethical considerations are considerable. Non-invasive dietary
interventions with pigs, however, may have an interest as the GIT
of pigs resembles very well the human GIT.
MODELING DISEASES TO SUBSTANTIATE HEALTH EFFECTS
Probiotic activity is situated on three main levels (Rijkers et al.,
2010): (i) inﬂuence on the growth or survival of pathogenic
microorganisms in the gut lumen (level 1), (ii) improvement of the
mucosal barrier function and the mucosal immune system (level
2) and, (iii) beyond the gut, effects on the systemic immune system,
remote organs and systems such as the liver and the brain (level
3). Correspondingly, in vivo approaches intended to substantiate
probiotic effects might consider these three levels through gas-
trointestinal infection models, mucosal immune disorder models
and models dealing with dedicated experimental neuro-metabolic
pathologies respectively.
Maintainingor improvingoverall“health”is difﬁcult to demon-
strate in humans and a fortiori in animals. Health claim evidence
for probiotics obviously starts by proving innocuousness of the
probiotic strain and its matrix and by clearly establishing its safety,
using adapted procedures (Vankerckhoven et al., 2008; Sanders
et al., 2010). In a second step, the model must ﬁt the purpose of
showing convincingly the projected functionality of the probiotic
strain, either in a prophylactic or therapeutic way, or demon-
strating a reduction of risk activity. This functionality must be
illustrated either using read-outs that are relevant for the human
situation, in appropriate terms of expected changes inmetabolism,
physiology, immunology, etc. or by a measurable limitation of the
severity or frequency of disease. Discriminating, relevant physio-
pathological markers are crucial and should reﬂect the targeted
probiotic functionality. Clearly, the anti-infectious impact of pro-
biotics, depicted for example by the survival rate of a deﬁned
pathogen, can only be considered for that particular pathogen and
should not be extended to other infections. Consequently, opti-
mal read-outs have to be selected as clear markers of pathology. In
the case of inﬂammation, various pathological as well as beneﬁcial
changesmay take place. For instance,we routinely determine IL-10
production in inﬂamed tissues and observed increased amounts
of this anti-inﬂammatory cytokine in the colon of mice following
TNBS or dextran sodium sulfate (DSS) treatment, as compared
to healthy mice. While IL-10 is a “regenerating” mediator, rapidly
induced by injured tissues in response to damage (Barada et al.,
2007), it is not an appropriate marker for efﬁcacy in inﬂamed
situations, where IL-10 is to be considered a marker of inﬂam-
mation. However, in the context of a healthy mucosa, probiotics
and other prophylactic anti-inﬂammatory drugs may be able to
substantially increase baseline levels of IL-10 and TGF-α, and thus
prevent further injuries.
INTESTINAL MODELS FOR INFLAMMATION AND INFECTION
For the evaluation of the anti-inﬂammatory activity of bacteria,
several colitis models can currently be used. In many cases the
reduction of chemically induced inﬂammation, e.g., induced by
TNBS or DSS, is measured (see Claes et al., 2011 for a complete
review). These models are mostly acute models, while chronic
ones are less common. They obviously only mimic symptoms of
IBD such as UC and CD but do not cause the real disease. There-
fore, each model has its own speciﬁcity and some interventions
may have opposite effects in different models. TNBS evokes an
inﬂammatory process involving T cells while the acute DSS model
is more likely to induce epithelial barrier disturbances (Foligne
et al., 2010a).
The IL-10 KO mouse model may also be used to study probi-
otics, but the spontaneous colitis that progressivelywill occur is not
homogenous, difﬁcult to control in time and highly dependent on
animal facility conditions. Sometimes additional treatments such
as Helicobacter infections or small amounts of DSS are required to
trigger the onset of inﬂammation. Clearly, the choice of a model
will depend on the putative mode of action of the probiotic used.
The IL-10 KO mouse model abolishes a key regulatory cytokine
and may thus exclude a virtually protective probiotic if the main
mechanism is IL-10 dependent. Similarly, while nod1/nod2 KO
mice are good models for CD, the fact that they lack the cellular
receptor for peptidoglycan and derived anti-inﬂammatory prod-
ucts (i.e., certain muramidyl di- or tri-peptides), will at the same
time exclude the efﬁcient study of bacteria that execute their anti-
inﬂammatory effect in this way (Macho Fernandez et al., 2011). In
general, KO mice models, especially those deﬁcient for key recep-
tors such as TLRs, are appropriate for case-by-case studies, often
aiming at conﬁrming speciﬁc mechanisms of action, but are less
suitable for broader screening purposes.
Finally, some other models of colitis involve adoptive transfer
of speciﬁc T cells (CD4+CD45rb) in immune-deﬁcient animals
(SCID, Rag−/−) allowing to explore the impact of probiotics on
adaptive immunity. Citrobacter rodentium is a murine pathogen
that induces, depending on the genetic background of the mice,
variable degrees of infectious and inﬂammatory responses, rang-
ing from infectious colitis to severe and fast lethal inﬂammation.
It shares several pathogenic mechanisms with enteropathogenic
E. coli (EPEC) and enterohaemorrhagic E. coli (EHEC), two clini-
cally important human gastrointestinal pathogens, showing severe
adhesion-based virulence in the intestinal mucosa. The models
also display crypt hyperplasia, demonstrating similarities with
pre-carcinogenic states. Some probiotics have been shown to pos-
itively alleviate C. rodentium-induced colitis as demonstrated for
lactobacilli, biﬁdobacteria, propionibacteria, yeasts and spores of
Bacillus subtillis (Chen et al., 2005; Johnson-Henry et al., 2005;Wu
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et al., 2008; Foligne et al., 2010b; Collins et al., 2014). This model,
when appropriately used, can be considered a model of choice
to investigate overall probiotic functionality (Borenshtein et al.,
2008) as it reveals information on the anti-infectious as well as the
anti-inﬂammatory potential of the strains tested.
Clostridium difﬁcile can be the causative agent of primary and
recurrent antibiotic-associated diarrhea and colitis in hospitalized
patients. Mice models to mimic this type of infection exist but
require the administration of a broad range of antibiotics that are
not always compatible with the planned probiotic interventions
(Chen et al., 2008; Sun et al., 2011). Therefore, the preferential use
of yeasts such Saccharomyces boulardii has been suggested (Barc
et al., 2008), or the window of intervention is to be kept quite
short to demonstrate substantial effects (Kaur et al., 2010). Par-
tial efﬁcacy has been shown on inﬂammation or stool consistency
parameters, although the infectionwas not completely cured (Fitz-
patrick et al., 2011). Further efforts are needed to optimize the
model for more detailed study of promising probiotic strains.
Similarly to Clostridium difﬁcile, a Salmonella typhimurium
infection in mice requires the administration of antibiotics dur-
ing the colonization (Hapfelmeier and Hardt, 2005), limiting also
the readouts of the model. However, infectious challenges with
S. enterica can be useful to study mortality and translocation
(Zoumpopoulou et al., 2008; de LeBlanc Ade et al., 2010; Zacarias
et al., 2014), focusing on indirect anti-inﬂammatory effects and on
the impact of the probiotics on the intestinal barrier.
Finally, listeriosis is not spontaneously modeled in mice and
infectivity would require genetically modiﬁed humanized animals
having the necessary receptor to allow the pathogen to attach
and disseminate within the host. When established, it might
allow to explore anti-infective probiotic potentials against Listeria
(Archambaud et al., 2012).
CANCER MODELS
While animal models exist for chemopreventive and chemother-
apeutical drugs for e.g., mammary and ovary cancer, bladder,
and prostate cancer, esophagus and colon cancer, lung and pan-
creas cancer, skin head and neck cancer, most studies involving
probiotics focused on colorectal cancer (CRC), as it represents
the most common malignancy of the GIT and has been linked
to dietary habits and a Western lifestyle. Many indications have
indeed pointed toward the importance of the microbiota in the
increased risk for CRC development. Several possible mechanisms
for reducing the risk for CRC development have been suggested,
each supported by in vitro and in vivo models (Uccello et al.,
2012). Probiotic intervention intends to alter the metabolism of
the microbiota by reducing intestinal enzymes that promote the
production of potential carcinogenic substances: β-glucuronidase
that produces aglycons, or nitroreductase and azoreductase, which
produce free amines from aromatic nitroso compounds and azo
dyes respectively (Goldin and Gorbach, 1984).
A second mechanism includes the direct inactivation of poten-
tial carcinogenic compounds, such as mutagenic derivatives of
heterocyclic aromatic amines. Commensal bacteria have been
found to bind or metabolize these compounds, resulting in
reduced mutagenicity in HCA exposure models (Kumar et al.,
2010), reduced bioavailability of other mutagens in the GIT and
tissues in mice (Orrhage et al., 2002) or increased detoxiﬁcation in
rats (Challa et al., 1997). Another way to study probiotic efﬁciency
in reducing the prevalence of CRC is the IL-10 KO mice model
(O’Mahony et al., 2001), leading to spontaneous colitis and colon
cancer development.
Improving the host’s immune response by activation of
antigen-presenting cells, natural killer cells or subsets of T and B
cells is another way to promote antitumor activity in mice (Sekine
et al., 1985) andmay explain some of the observations in syngeneic
mice and guinea pigs on Lewis lung carcinoma and line-10 hep-
atoma (Matsuzaki et al., 1985), as well as in bladder cancer in man
(Aso et al., 1995). The same probiotic strain was also shown to
have a positive effect on transplantable tumor cells and to sup-
press chemically-induced carcinogenesis in rodents (Matsuzaki
et al., 1988). A component of the polysaccharide peptidoglycan
complex was shown to improve colitis-associated cancer in mice
(Matsumoto et al., 2009). Measuring survival rates of mice injected
with tumor cells is another model that can be used to test or com-
pare the potential of different probiotic strains to increase cellular
immunity (Lee et al., 2004).
Anti-proliferative effects by regulation of apoptosis and cell
differentiation have been described in response to the carcino-
gen azoxymethane (AOM; Le Leu et al., 2005), which may be
linked to reduced levels of ornithine decarboxylase involved in
polyamine biosynthesis (Moorehead et al., 1987). Butyrate also
enhances cellular differentiation and reduces proliferation (Top-
ping and Clifton, 2001). Butyrate may be used as an energy source
by the colonocytes and together with other SCFAs theymay reduce
the colonic pH and the concentration of secondary bile salts. In
addition, conjugated linoleic acids (CLAs) were also shown to have
anti-inﬂammatory and anti-carcinogenic effects (Kim and Park,
2003; Ewaschuk et al., 2006; Evans et al., 2010), possibly through
the activation of PPARγ.
Besides for CRC, the ApcMin mouse model can also be used
in the case of mammary tumorigenesis (Moser et al., 1995). Chen
et al. (2009)used thismodel to examine thequantitative andmech-
anistic effects of probiotic yeast on the induction of intestinal
tumors. Clearly a large number of models exist for the investiga-
tion of probiotic activities on cancer, reﬂecting the many possible
mechanisms of probiotic activity, as well as the intense cancer
research activity.
MODELS LOOKING INTO METABOLIC DISORDERS
Metabolic syndrome (MS) is a complex multifactorial disorder
involving genetic predisposition, life style, diet, and environmen-
tal factors and is almost always accompanied by an increased risk
of cardiovascular diseases and type 2 diabetes, and possibly also
non-alcoholic fatty liver disease (NAFLD) and hypertension. Obe-
sity is the most important precursor for MS, especially on a longer
term. Pro- and prebiotics can play a role in weight management, as
obesity was found to be linked to a dysbalance of the microbiota,
both in mice and man (Ley et al., 2005). Turnbaugh et al. (2008)
investigated the inter-relationship between diet, microbial ecology
of the gut and energy balance using aWestern diet-induced obesity
model in mice. This diet induced a dominance of the Firmicutes
in the distal gut microbiota which could be reversed by subse-
quent dietary manipulations to limit weight gain. Interestingly
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the transplantation to germ-free lean mice of the microbiota from
mice with diet-induced obesity, increased signiﬁcantly more the
adiposity in the recipient mice than transplants from lean donor
mice. Possible mechanisms include a change in intestinal perme-
ability, leading to decreased translocation of lipopolysaccharides
in the microbiota of lean mice and therefore to decreased inﬂam-
mation and abdominal adiposity (Cani et al., 2008). Also the
importance of A. muciniphila in this process has recently been
illustrated (Everard et al., 2013). Overall these observations have
fuelled the idea of using probiotics and prebiotics in dietary strate-
gies for weight management (Nicholson et al., 2005; Cani et al.,
2009). Again, several mechanisms, and thus several models, can
be considered to improve gut microbial balance: CLA production
(Lee et al., 2006), polyphenol supplementation, low amounts of
probiotics (Rastmanesh, 2011), prebiotic intake, decreased food
intake, increased satiety, increased barrier function or ways to
decreased abdominal adiposity or total cholesterol levels (Yadav
et al., 2008). Since it is impossible to describe all MS related animal
models here, it is important to note that the cause/consequence
relationship is not clear when only considering the composition
change of the microbiota related to obesity, as many of the models
involve high-fat diets, also directly affecting the microbial compo-
sition (Hildebrandt et al., 2009). The use of germ-free mice with
standardized nutrition might help to study the direct impact of a
particular microbiota composition on MS. The observed shifts in
the microbiota composition may have an impact on the barrier
function, but they have also been linked to functional shifts (e.g.,
production of SCFAs) in the microbiota which can contribute to
an obese phenotype (Turnbaugh et al., 2006). Important to notice
as well, is the observation that the situation in humans seems to be
different from mice, since bacteroidetes-related taxa were either
reported to increase, to remain unchanged, or to decrease after
weight loss (Duncan et al., 2008; Nadal et al., 2009). The detec-
tion of the ob and db genes in mice led to the development of
several animal models to study obesity effects (Ingalls et al., 1950;
Hummel et al., 1966; Comuzzie and Allison, 1998). The ob gene,
located on chromosome 6, encodes the hormone leptin and ren-
ders ob/ob mice massively obese, with marked hyperphagia and
mild transient diabetes, while the db gene, located on chromo-
some 4, codes for the leptin receptor and renders the db/db mice
markedly obese with hyperphagia, but with severe, life-shortening
diabetes.
One can conclude that the complex interplay between genetics,
environment, diet, the microbiota and its metabolism or the bar-
rier and immune function of the host, make it difﬁcult to develop
all-round animal models. Partial mechanisms may need to be put
forward for independent evaluation, with the total picture being
obtained through the combination of different in vitro and in vivo
models. Translation from animal to man may also prove to be
difﬁcult, because of this complexity.
MODELS FOR AUTO-IMMUNE DISEASES
Similarly to MS, auto-immune disease (AID) covers a broad range
of possible diseases (type 1diabetes,multiple sclerosis, rheumatoid
arthritis, pemphigus vulgaris, scleroderma, Sjögren’s syndrome,
etc.) involving, besides genetic factors, also an aberrant intesti-
nal microbiota, a disturbed mucosal barrier and altered intestinal
immune responsiveness. All these factors share functional links
and will therefore determine the models to be considered for
more in depth study of probiotic mechanisms or for comparing
different strains. Since probiotics have the potential to inter-
fere with all three factors, one will need to try and ﬁnd strains
that have the capacity to change in a positive direction any, or
any combination, of these factors. As for the intestinal immune
responsiveness, interest will be in anti-inﬂammatory probiotics,
as chronic inﬂammation underlies many AIDs and is often at
the start of its development, as in rheumatoid arthritis. It is also
not clear if the AID is caused by inﬂammation, or the other way
around.
Animal models such as the non-obese diabetic mice will spon-
taneously develop diabetes resembling human insulin-dependent
diabetesmellitus (Gepts and Lecompte, 1981; Kataoka et al., 1983).
The fact that in these mice a progressive lymphocytic inﬁltra-
tion of autoreactive CD8+ T cells into the islets of Langerhans
will cause insulitis positioned the model as a model of AID. In
another model, considered a good model of rheumatoid arthri-
tis in humans, a probiotic strain prevented the onset of type
II collagen-induced arthritis in DBA/1 mice (Kato et al., 1998).
Results suggest that the probiotic was able to modify the systemic
humoral and cellular immunity and could elicit alterations of the
immune state in this model. In general there are many conﬂicting
data on the effect of probiotics in AID. In part this uncertainty
comes from the diversity of the strains evaluated, while the differ-
ent genetic backgrounds of the host might also be an important
reason.
FUTURE PERSPECTIVES FOR THE USE OF IN VIVO TESTS IN PROBIOTIC
RESEARCH
To increase the accuracy of animal models,multi-humanized mice
can be considered, carrying functional human genes, cells, tissues,
or organs. Immune-deﬁcient mice are often used as recipients for
human cells or tissues, because they can relatively easily accept
heterologous cells due to lack of host immunity. Traditionally,
nude mice and severe combined immunodeﬁciency (SCID) mice
have been used for this purpose, but many other models have been
shown to engraft human cells and tissues evenmore efﬁciently (Ito
et al., 2008). These humanized mouse models may assist to model
the human immune system in various scenarios of health and
disease, and may enable the evaluation of therapeutic candidates
in an in vivo setting more close to human physiology. While those
speciﬁc humanized mice are commonly used in biological and
medical research for human therapeutics, they do not frequently
appear in probiotic research yet.
Given the importance of the microbiota for many immune and
metabolic functionalities of the host, the development and use
of mice models with an artiﬁcially composed microbiota, e.g., a
human microbiota, might help to better mimic the human con-
dition. The use of axenic or monoxenic mice may help to unravel
the “egg or the chicken” question mentioned above. The impact
of a dietary intervention with or without a microbiota can learn
interesting things about the direct inﬂuence of the administered
probiotic versus e.g., an indirect metabolic or microbiological
effect or can show the direct impact on the immune system of
any planned intervention.
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As for the ethical problem of using animal models, interest-
ing developments such as seen at the Wageningen University in
The Netherlands, may bring some solution in the future. In sil-
ico solutions may try to represent the interactions of the pig gut,
the nutrients and other feed/food components with the residing
microbes and with epithelial cells. All elements are considered as
nodes in a mathematical model, together with their mutual, quan-
titative dependencies2. Using these model interactions, a number
of higher level processes related to intestinal immunity, tolerance
and barrier functions can possibly be simulated, and conditions as
gut homeostasis could possibly be better understood. On a longer
term, the model may even evolve into a dynamic and predictive
one, allowing to test hypotheses.
DISCOVERING PROBIOTICS WITH GENETICS AND OMICS
STRESS RESPONSES
Over thepast twodecades several attempts havebeenmade to iden-
tify molecular markers that would facilitate the rapid selection of
probiotic strains (Table 3). To elucidate the complex adaptation
mechanisms of probiotic microorganisms under stress conditions,
several genetic and omics studies have been conducted in an
attempt to identify gene expression and/or protein production
patterns related to stress. The exposure of cells to gastric acid-
ity causes reduction of intracellular pH, which adversely affects
numerous cell wall and transmembrane-based processes and dam-
ages proteins, nucleic acids and other cellular macromolecules. To
resist acid stress, microorganisms employ mechanisms aiming at
the maintenance of the intracellular pH homeostasis, the repair of
macromolecular structures like the cell envelope or ribosomes and
other damagedmolecules (Lebeer et al., 2008). Heat shockproteins
are molecular chaperones involved in the repair of acid-damaged
proteins. Many studies have demonstrated that several heat shock
proteins, e.g., DnaK, GroES, GroEL, GrpE are induced by acid
stress, but their induction varies among different species/strains
(Hamon et al., 2014). In parallel, the Clp proteases (e.g., ClpP,
ClpE, ClpL) are also induced under acid stress targeting denatured
proteins to re-fold them to the appropriate structure or to degrade
them if they are beyond repair (Ferreira et al., 2013; Hamon et al.,
2014). Genes implicated in DNA repair were also found to be up-
regulated under acidic stress (e.g.,uvrB,uvrD1, vsr; Jin et al., 2012).
Furthermore, an essential component in the response against low
pH is the up-regulation of the F1F0-ATPase (Sanchez et al., 2008;
Jin et al., 2012; Koponen et al., 2012). The various subunits of this
multimeric enzyme are being encoded by eight genes found on
the atp acid inducible operon. The F1F0-ATPase lowers the cyto-
plasmic concentration of protons by virtually extruding them to
the extracellular environment at the expense of ATP which can
ultimately lead to energy depletion and growth arrest. The com-
position of the cell envelope is also altered upon exposure to acidic
conditions to decrease its permeability to protons. Genes and pro-
teins involved in peptidoglycan biosynthesis (e.g., manB, glmU,
dapA, glycosyltransferases), in D-alanylation of lipoteichoic acids
(e.g., dlt operon), in fatty acid (e.g., fab genes) and exopolysaccha-
ride (EPS; e.g., Etk-like tyrosine kinase) biosynthesis were induced
2http://www.wageningenur.nl/en/project/Models-of-dietary-effects-on-immune-
responses-in-pigs-6.htm
to ameliorate the cells’ resistance to acid stress (Perea Velez et al.,
2007; Jin et al., 2012; Koponen et al., 2012). In addition proteins
involved in cell envelope biogenesis (e.g., FabF, RfbB, RfbC) were
shown to have a strain-speciﬁc role in acid tolerance (Hamon
et al., 2014). The gene luxS exhibited enhanced expression under
acidic conditions in several probiotics, implicating quorum sens-
ing (QS) in acid stress resistance (Moslehi-Jenabian et al., 2009;
Koponen et al., 2012).
As discussed above, having survived the hostile environment
of the stomach, probiotics next have to face bile in the duode-
num. Many transcriptomics and proteomics studies have been
performed to determine bile resistance factors in probiotic strains.
Interestingly, several of the pathways that are activated during acid
stress in the stomach seem to be involved in the ability of probi-
otics to adapt to bile, as well. Responses against bile include the
increased expression of molecular chaperones (e.g., GroEL,GroES,
HSP20, DnaK), proteases (e.g., Clps, DegQ), DNA repair proteins
(e.g., helicase) and of the F1F0-ATPase (Wu et al., 2010; Hamon
et al., 2011; Ruiz et al., 2012; Ferreira et al., 2013; An et al., 2014).
Genes involved in EPS (e.g., eps, welG) or fatty acid biosynthe-
sis (e.g., acc, fab) have been found down-regulated (Koskenniemi
et al., 2011; An et al., 2014). In contrast the dlt operon was up-
regulated (Koskenniemi et al., 2011). It is generally accepted that
cells attempt to protect the integrity of the cell envelope by appro-
priately regulating cell wall and cell membrane processes (Lebeer
et al., 2008). Apart from these generic mechanisms that may also
be induced by other stresses, there are some that are obviously
speciﬁc for bile stress. The BSHs encoding genes were found to
be up-regulated under bile stress in many studies (Hamon et al.,
2011; Koskenniemi et al., 2011; An et al., 2014). However, this
is not always the case indicating differences in the regulation of
BSH among probiotic strains (Sanchez et al., 2007). Bile export
from the cell is another mechanism to counterbalance bile toxi-
city. Permeases of the major facilitator superfamily (MFS) have
been found to be up-regulated and could play a similar role
with the bile-inducible efﬂux transporter BetA. Also ABC (ATP-
binding cassette) transporters could play a role in bile expulsion
(Koskenniemi et al., 2011; Ruiz et al., 2012; An et al., 2014). Pro-
biotic microorganisms also use multidrug resistance (MDR) bile
efﬂux transporters to actively pump bile salts out of the cyto-
plasm. Several MDR genes (e.g., betA, ctr) have been reported to
be induced under bile stress (Price et al., 2006; Gueimonde et al.,
2009).
The molecular basis of the stress physiology of LAB and other
probiotics has advanced rapidly over the past years (Bron et al.,
2011; Upadrasta et al., 2011). As our understanding of the stress
response mechanisms have increased, a plethora of genes could
have been selected as molecular markers for identifying robust
probiotic strains. However, this approach has not been followed
yet for a number of reasons. A closer look at the lists of genes
involved in stress resistance reveals that many of them are well
conserved and thus their presence does not reveal anything for the
strain under investigation (e.g., heat shock proteins, F1F0-ATPase,
etc.). In fact, several of them are housekeeping genes involved in
central cellular processes and thus it is unlikely that they will be
missing from the bacterial genome. In such cases it is the enzymatic
activity of the relevant protein or protein complex that is
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decisive and it needs to be experimentally conﬁrmed. For example
a bile-resistant mutant of Biﬁdobacterium lactis subsp. animalis
overexpessing the F1F0-ATPase resisted acid stress better than the
parental strain (Sanchez et al., 2006). Finally, at this stage, very
few genes could be directly related to the robustness to a speciﬁc
stress. The presence of BSHs genes as an example, is indicative for
resistance to bile stress. However, this information on its own is
not sufﬁcient to provide us with the overall behavior of a strain
under the multitude of probiotic stresses. The identiﬁcation of
more sequences, linked to their respective speciﬁc phenotypes,
may lead to the construction of databases with a more predictive
value.
ADHESION TO THE HOST
As discussed above, adhesion to the host’s cells could be a signiﬁ-
cant characteristic of probiotics. Temporary colonization may be
necessary for the probiotic to exert its properties e.g., the compet-
itive exclusion of pathogens and the modulation of the immune
system. A potential mechanism for adhesion to the host implicates
the binding of molecules exposed on the surface of microbial cells
to the mucus layer of the host’s intestine. Mucus-binding proteins
(Mubs) hold an important role in the process of probiotics’ adher-
ence to the host. Mubs are cell-surface proteins, characterized by
the presence of a C-terminal cell wall anchoring motif (LPXTG)
and multiple Mub repeats, homologous to the MucBP domains
(Boekhorst et al., 2006) which bind to mucins and glycans. Several
mub genes and Mub proteins have been determined in probiotic
strains (Azcarate-Peril et al., 2008; Mackenzie et al., 2010; Weiss
and Jespersen, 2010; Turpin et al., 2012). Surface (S-) layer pro-
teins also play a pivotal role in the adhesion of probiotics. The
slpA gene encoding the surface-layer protein A (SlpA) has been
shown to be involved strongly in adhesion capacity (Ashida et al.,
2011; Beganovic et al., 2011; Turpin et al., 2012) and has been also
identiﬁed in the genome of probiotic propionibacteria (Falentin
et al., 2010). Some probiotic strains which are devoid of S-layer
proteins, encode the aggregation promoting factor (Apf) which
shares several features with the S-layer proteins (Ventura et al.,
2002; Turpin et al., 2012). Additionally, sortase-dependent surface
proteins may also play an important role concerning the adhe-
sion to the host. It has been demonstrated that disruption of the
housekeeping sortase gene srtA led to reduced bacterial adhesion
to epithelial cells (Munoz-Provencio et al., 2012). A major target
for bacterial adhesins is ﬁbronectin, an extracellular matrix glyco-
protein. A transcriptomics study revealed that the gene encoding
a ﬁbronectin-binding protein was signiﬁcantly up-regulated dur-
ing incubation in duodenal juice and bile (Weiss and Jespersen,
2010). Genome analysis of a probiotic strain showed that the
presence of FbpA protein may be responsible for adhesion to the
extracellular matrix of epithelial cells (Azcarate-Peril et al., 2008).
In a recent study, Vastano et al. (2014) demonstrated that the
moonlighting protein E1 β-subunit of the pyruvate dehydrogenase
complex, which is encoded by the pdhB gene, is an element related
to ﬁbronectin-binding. Some probiotic strains are equipped with
proteinaceous surface appendages, such as pili or ﬁmbriae, which
facilitate their adhesion to human gut cells. In Gram positive bac-
teria the assembly of pili relies mostly upon a sortase-dependent
mechanism (Mandlik et al., 2008). Gene clusters responsible for
the biosynthesis of pili have been identiﬁed in the genomes of pro-
biotic lactobacilli (e.g., spaCBA, spaFED; Kankainen et al., 2009;
Douillard et al., 2013) and biﬁdobacteria (e.g., pil2, pil3, ﬁm1,
ﬁm2, ﬁm3; Gilad et al., 2011; Westermann et al., 2012; Turroni
et al., 2013). Moreover, genetic analysis of several probiotic biﬁ-
dobacteria strains revealed the existence of pilus gene clusters in
their genome. Each cluster was organized in an operon and con-
tained themajor pilin subunit-encoding gene (ﬁmA or ﬁmP) along
with one or two minor pilin subunit-encoding genes (ﬁmB and/or
ﬁmQ) and a gene encoding a sortase enzyme (strA; Foroni et al.,
2011). Genes involved in the assembly of the tide adherence (Tad)
pilus found in biﬁdobacteria has also been reported (Westermann
et al., 2012). Proteomic and genomic analyses have shown that
moonlighting proteins (e.g., ENO, GAPDH, EF-Tu) and proteins
related to stress response (e.g., DnaK, GrpE, GroEL, GroES) pro-
mote the adhesion of probiotics (Sanchez et al., 2005; Candela
et al., 2009; Izquierdo et al., 2009; Gilad et al., 2011; Turpin et al.,
2012; Le Marechal et al., 2014).
In contrast to stress related genes, genes involved in adhesion
may be more informative about the properties of a strain. The
presence of genes encoding adhesive molecules is still considered
beneﬁcial for selecting a probiotic strain as it might increase its
interaction with the host. The adhesion biology of bacteria (both
probiotics and pathogens) is a ﬁeld evolving fast and detailed
molecular mechanisms are being elucidated. These developments
are expected to signiﬁcantly improve the selection of probiotic
strains. For example in silico analysis of these molecules may help
to determine the nature of the adhesion sites (e.g., binding to
ﬁbronectin, mucin, etc.). Validation of the predicted adhesive
potential of a strain is relatively straightforward with in vitro and
in vivo assays as described earlier.
HUMAN MILK OLIGOSACCHARIDES AND MUCUS DEGRADATION
Mucins can modulate bacterial colonization as a direct energy
source (Derrien et al., 2010). The gene pool of biﬁdobacteria con-
tains several genes involved in the metabolism of human milk
oligosaccharides (HMOs) and host-derived carbohydrates, like
mucins. These genes allow the adaptation of these bacteria to
the human GIT (Pokusaeva et al., 2011; De Bruyn et al., 2013).
Genomic analysis of several biﬁdobacterial strains has given use-
ful insights about the molecular mechanisms supporting these
processes.
The genome sequence of B. longum subsp. infantis ATCC
15697 was found to contain a novel 43 kbp gene cluster encod-
ing genes predicted to be involved in the catabolism of HMOs
(Sela et al., 2008) as well as a great number of solute binding pro-
teins (F1SBPs). The latter are part of ABC transporters and they
are associated with the import of oligosaccharides. Furthermore,
the expression of speciﬁc binding proteins related to HMO iso-
mers import was induced under growth on HMO (Garrido et al.,
2011). It was also shown that this probiotic bacterium uses two
different β-galactosidases for the degradations of type-1 and type-
2 HMOs (Yoshida et al., 2012; De Bruyn et al., 2013). Furthermore,
in the genome sequence of B. animalis subsp. lactis AD011, several
glycosylases were identiﬁedwhich are associated with the degrada-
tion of HMOs (Kim et al., 2009). Proteomic analysis of B. biﬁdum
PRL2010 showed that among the mucin induced proteins were
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a variety of glycosyl hydrolases, while transcriptional proﬁling
led to the identiﬁcation of several mucin-induced genes encod-
ing for different components (e.g., exo-α-sialidases, fucosidases,
PTS systems, ABC-type carriers, speciﬁc permeases; Turroni et al.,
2010a, 2011). Two B. biﬁdum strains containing engBF and afcA
genes, encoding for endo-α-N-acetylgalactosaminidase and 1,2-
α-L-fucosidase respectively, were able to degrade high-molecular
weight porcine mucin in vitro. The expression of both genes was
highly induced in the presence of mucin (Ruas-Madiedo et al.,
2008). Moreover, two novel α-N-acetylgalactosaminidases from
B. biﬁdum JCM 1254 have been identiﬁed, NagBb (Kiyohara
et al., 2012) and AgnB (Shimada et al., 2014). These enzymes
exhibit activity against the core structures in mucin O-glycans.
Concerning the probiotic lactobacilli, proteomic analysis of Lac-
tobacillus fermentum I5007 after exposure to jejunal environment
in vivo, disclosed the induction of a glycoside hydrolase, a mucin
degrading enzyme (Yang et al., 2007).
In addition, mucins play a crucial role in the protection of the
intestinal barrier function. Mucin degradation by intestinal bacte-
ria and its use as a carbon source stimulate goblet cells to increase
mucus production. Probiotics may also inﬂuence the production
of mucin directly during adhesion or through other mechanisms.
A mutant of the probiotic L. plantarum 299v strain lacking the
adhesion gene (adh), lost the potential to induce mucin secretion
(Mack et al., 2003). A recent study demonstrated that the soluble
protein p40 from the probiotic strain L. rhamnosus GG, stimulates
the activation of epidermal growth factor receptor (EGFR), which
promotes the up-regulation of mucin production in goblet cells.
Therefore p40 may contribute to the protective mechanism of the
intestinal epithelium from injury and inﬂammation (Wang et al.,
2014).
The ability of probiotics to degrade hosts glycans and use host
oligosaccharides as an energy source is a very important property.
The presence of genes whose products are involved in these pro-
cesses in the genome of a strain is a clear indication about the
adaptation of this particular strain to the GIT. Such strains may
have a competitive advantage over other strains in prevailing and
colonizing the GIT. The stimulation of mucin production by pro-
biotics is also very interesting as it can facilitate increased binding
sites for probiotics and improved gut barrier functions.
MODULATION OF THE IMMUNE SYSTEM
Probiotic bacteria canmodulate the response of the host’s immune
system, interacting with IECs and DCs. It was demonstrated that
the p40 and p75 proteins, puriﬁed from L. rhamnosus GG, stimu-
late activation of protein kinase B (Akt), promote cell growth, and
inhibit TNF-α (Yan et al., 2007). Homologues of these proteins
have been also found in several L. casei strains (Yan et al., 2007;
Bauerl et al., 2010). The study on the extracellular proteome of B.
animalis subsp. lactis BB-12 revealed six proteins with potential
immunogenic effect (e.g., ClpB and Rpf; Gilad et al., 2011). In L.
plantarum strains, six genetic loci were determined with poten-
tial impact on the production of the cytokines IL-10 and IL-12
by PBMCs. These loci included genes which might induce anti- or
pro-inﬂammatory immune responses in the intestine (vanHemert
et al., 2010). Genetic loci that might regulate the immune response
of DCs were also identiﬁed in L. plantarum WCFS1 (Meijerink
et al., 2010). SlpA has been shown to induce IL-10 production in
DCs (Konstantinov et al., 2008) and to intensify immune protec-
tion by conferring resistance to infection by Salmonella enterica
serovar Typhimurium FP1 (Beganovic et al., 2011). Moreover,
proteomic analysis of the surface proteins of Propionibacterium
freudenreichii ITG P20 strain revealed that several SLPs (e.g., InlA,
LspA, SlpE, SlpA, SlpB) are contributing factors in the induction
of the IL-10 and IL-6 regulatory cytokines (Le Marechal et al.,
2014).
Serine protease inhibitor (serpin)-encoding genes (ser) are
found in several biﬁdobacteria and they are involved in the inhibi-
tion of elastases, components related to intestinal inﬂammation
(Turroni et al., 2010b). It has also been shown that B. breve
UCC2003 produces a cell surface-associated EPS, encoded by each
half of a bidirectional gene cluster, which evokes a weak adap-
tive immune response and it provides protection against the gut
pathogen Citrobacter rodentium (Fanning et al., 2012).
Defensins are inducible antimicrobial peptides of the innate
immune system, which play an important role in host defenses
(Ganz, 2003). It has been demonstrated that the protein ﬂag-
ellin, produced by the probiotic strain E. coli Nissle 1917, induces
the expression of human β-defensin 2 (hBD-2) by the intesti-
nal epithelium (Schlee et al., 2007). Mutants devoid of the gene
responsible for the production of ﬂagellin, presented decreased
ability to induce hBD-2.
Our understanding of the mechanisms involved in the mod-
ulation of the host’s immune responses by probiotics is far from
complete. Even though several genetic and omics studies have
shed some light on the relevant mechanisms there is much ground
to be covered. Novel developments in meta-transcriptomics and
meta-proteomics are expected to speed up research in this ﬁeld
since they will allow the direct study of the interactions between
microorganisms and the cell of the host. Currently, it is very difﬁ-
cult to determine a priori whether a strain couldmodulate immune
responses (beneﬁcial or not), based solely on sequence data. This
is the main reason making it necessary to assess immunomodula-
tory properties during screening for probiotics with in vitro and/or
in vivo tests.
PRODUCTION OF ANTIMICROBIAL COMPOUNDS
Probiotic strains often produce an array of antimicrobial com-
pounds. Several of these, like organic acids (e.g., lactic acid)
are primary metabolites. In most of these cases, the molecu-
lar players of these metabolic pathways for those molecules have
been well studied. Other antimicrobial compounds are secondary
metabolites, like bacteriocins. The biosynthetic regulons of many
bacteriocins have been described and their mode of action has
been elucidated. The beneﬁcial effect of bacteriocin-producing
probiotic strains against invasive enteropathogens has been well
established in vivo. It has been demonstrated that the bacteriocin
Abp118, produced by L. salivarius UCC118, was active against
Listeria monocytogenes in mice (Corr et al., 2007). High through-
put sequencing of bacterial genomes allows the rapid identiﬁcation
of genetic loci related to bacteriocin production and/or immunity.
However, bacteriocins should not strictly be considered as antimi-
crobials. For example it has been demonstrated that six genes of L.
plantarumWCFS1 associatedwith the plantaricin biosynthesis and
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secretion, regulated the production of pro- and anti-inﬂammatory
cytokines of DCs (Meijerink et al., 2010).
QUORUM SENSING
QS is a communication mechanism among bacterial cells which
allows the orchestrated expression of genes within bacterial pop-
ulations. Its function relies on signaling molecules known as
autoinducers. In Gram negative bacteria QS signaling relies on N-
acylhomoserine lactones (AHL), while in Gram positive bacteria
this procedure is dependent upon small cyclic and linear peptides
(Waters and Bassler, 2005).
In L. plantarum WCFS1 genome an agr-like two component
regulatory system, encoded by the lamBDCA operon, was identi-
ﬁed. This operon contained four genes encoding an autoinducing
signaling peptide (AIP) modiﬁcation protein (lamB), an AIP
(lamD), a membrane-located histidine protein kinase (lamC) and
a cytoplasmic response regulator (lamA). This system encodes for
a cyclic thiolactone autoinducing peptide (CVGIW) which reg-
ulates the adhesion capability of the strain (Sturme et al., 2005).
The same strain was shown to carry a second agr-like QS sys-
tem encoded by the lamKR operon, which was similar to the
lamBDCA operon, suggesting analogous function (Fujii et al.,
2008). The probiotic strain E. coli Nissle 1917 was shown to
produce AI-2 molecules (e.g., furanosyl borate diester), involv-
ing the luxS (autoinducer) gene expression. These molecules were
found to inﬂuence the induction of anti-inﬂammatory cytokines
in a mouse model of acute colitis (Jacobi et al., 2012). In L. aci-
dophilus NCFM, the transcription of the luxS gene was notably
increased after co-cultivation with live Listeria monocytogenes
cells, indicating the important role of signaling molecules to
the adhesion and the competitive exclusion of pathogens in the
GIT (Buck et al., 2009; Moslehi-Jenabian et al., 2011). B. ani-
malis subsp. lactis BB-12 produces a QS system related peptide
(CHWPR). It has been demonstrated that this peptide enhances
the expression of two genes in somatic cells, the gene c-myc, the
deregulation of which has been associated with several forms
of cancer, and IL-6, an anti- and pro-inﬂammatory cytokine
(Mitsuma et al., 2008). The role of AI-2 signaling molecule to
the adhesive potential of probiotic lactobacilli has also been
addressed. It has been established that the disruption of the luxS
gene reduced signiﬁcantly the adherence to IECs (Buck et al.,
2009).
QS is a very important aspect that may dramatically affect the
efﬁcacy of probiotics in vivo. Probiotics are entering an already
established microbiome, including established bioﬁlms, in which
they need to be incorporated. In such an ecological system inter-
and intra-species communication is vital to secure temporary col-
onization of the host, release of antimicrobial compounds and
competitive exclusion of pathogens. Evidently, there is an ongoing
communication between the microbiome (including any probi-
otic strain present) and the cells of the host, perhaps beyond
immunomodulation. Detailed knowledge about these phenomena
may allow us to optimize the probiotic effect.
PRODUCTION OF NUTRIENTS AND OTHER BENEFICIAL PROCESSES
Production of nutrients in the GIT by probiotic bacteria is an
essential process for both the host and the microbiome. In silico
genome analysis of two L. reuteri strains revealed genes responsi-
ble for the production of vitamins, essential amino acids, lactate
and SCFA (Saulnier et al., 2011). It was shown that both strains
hold complete biosynthetic pathways for folate and vitamin B12
and that one of the strains carried also a pathway for the produc-
tion of vitamin B1. Analysis of the P. freudenreichii CIRM-BIA1T
genome revealed genes associated with the production of SCFAs
and the precursor of menaquinone (vitamin K2), a biﬁdogenic
compound (Falentin et al., 2010). The fos gene cluster of B. ani-
malis subsp. lactis AD011 is another biﬁdogenic agent, since it is
implicated in the processing of health-promoting fructooligosac-
charides (Kim et al., 2009). This cluster was shown to have high
similarity to the relevant operon described for B. breve UCC2003
(Ryan et al., 2005). Furthermore, probiotic bacteria appear to
hold a signiﬁcant role in the modulation of nutrient absorp-
tion and in the regulation of the host’s energy balance. Several
biﬁdobacteria possess genes encoding forABCcarbohydrate trans-
porters. The latter contribute to the high consumption rate of
speciﬁc carbohydrates resulting in high production of acetate, a
metabolite which confers protection from enteropathogenic infec-
tion (Fukuda et al., 2012). Furthermore, genetic and proteomic
analysis of L. acidophilus A4 revealed that the catabolite con-
trol protein A (ccpA) is probably involved in the reduction of
total serum cholesterol by inﬂuencing the expression of several
membrane associated proteins. These proteins may play a role in
the adhesion of the cholesterol to the bacterial cells and conse-
quently, in the process of lowering blood cholesterol (Lee et al.,
2010).
FUTURE PERSPECTIVES FOR THE USE OF OMICS IN PROBIOTIC
RESEARCH
Several aspects of the molecular mechanisms that underpin pro-
biotic properties have been elucidated. Original studies relied
on molecular analysis of single genes and proteins. Over the
last decade the advent of omics technologies have allowed the
study of probiotic organisms at the whole genome level (Guei-
monde and Collado, 2012). Today, metagenomics methodologies
are revealing the composition of complex ecosystems and their
biology (Qin et al., 2010; Upadrasta et al., 2011). All niches of
the human body carry microbiomes that diverge according to the
speciﬁc compartment, the age and the dietary habits of the indi-
vidual and many other factors (Ravel et al., 2014). Meta-omics
offer for the ﬁrst time the proper tools for understanding the
in vivo behavior of probiotics in contrast to simulated condi-
tions involving pure or only a handful of microbial cultures. As
omics technologies become cheaper the genome sequencing of
microorganisms will become a routine practice. Incorporation
of novel functional data through high throughput transcrip-
tomics and proteomics into databases will ultimately facilitate
the in silico assessment of the probiotic potential of candidate
microorganisms. It is too early to speculate whether in silico anal-
ysis will totally abolish experimental approaches. It is certain
though that as our understanding of the molecular biology of
probiotic properties improves, we will be able to design more efﬁ-
cient and more sophisticated in vitro and in vivo tests. Finally
the cataloging of the human microbiome has already opened
up the door for considering new categories of microorganisms
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as potential probiotics beyond the usual suspects (i.e., LAB and
biﬁdobacteria).
CONCLUSION
In this review we presented a detailed overview of the differ-
ent methodologies employed for the discovery of new probiotic
strains. The diversity of screening assays is considerable and their
efﬁcacy variable. Some assays are more applicable for screen-
ing high numbers of strains while others are more appropriate
for validating the probiotic properties of a handful of strains.
There is no bulletproof procedure or workﬂow for selecting pro-
biotics than perhaps the actual testing of candidate strains on
the target population (Rijkers et al., 2010). However, consid-
ering the limitations of human trials, traditional in vitro and
in vivo assays along with novel omics approaches will remain
important. To take full advantage of probiotics for the health
of humans a methodological evolution is needed. For exam-
ple, new “humanized” animal models may be necessary to study
host–microbe interactions. Such developments need to go hand
in hand with improvements in legislation, ethics, if we want
to meet the scientiﬁc and technological challenges of probiotic
research.
Today, in most parts of the Western world, the acceptance of
health claim dossiers is very difﬁcult. In Europe the use of the
term “probiotic” has been banned in communications toward the
consumer. In the food area, except for a health claim on lac-
tose tolerance for yogurt, none of the 300 bundled health claim
dossiers have been approved. It can be hoped that amore profound
study of the mechanisms of action and a better understanding of
the microbiome functioning and its dynamics with the host, will
provide the health claim evaluation panels with the necessary evi-
dence to consider a wider legal acceptance of health claims. While
some of the technological evolutions mentioned in this review
have the potential to contribute signiﬁcantly to this, the willing-
ness to consider new types of probiotics, such as F. prausnitzii or
A. muciniphila, currently not yet available on the market, will be
crucial.
Not treated in this review is the importance of the production
process. With these new, highly anaerobic organisms such as F.
prausnitzii or A. muciniphila in mind, it will be important for pro-
biotic producers to come up with new production processes and
modiﬁed preservation and administration strategies to guarantee
the delivery of active strains to the consumer or patient. As several
papers have shown (van Baarlen et al., 2009; Lebeer et al., 2011,
2012; Bron et al., 2012; van Bokhorst-van de Veen et al., 2012)
the (industrial) processing of a probiotic preparation has a fun-
damental impact on the functionality in the host. Viability, the
presence or absence of pili, the cell wall condition, the matrix
or the growth stage of the probiotic, they all seem to have an
important inﬂuence on its performance and its interaction with
the host. Deﬁning the mechanism of action of a probiotic might
therefore also include some critical parameters of the production
process.
Without any doubt, the continued development of omics tech-
nologies will assist in alleviating the shortages currently faced
with the traditional in vitro and in vivo models. Although it may
take a while before we can predict probiotic functionality directly
from genomic and metagenomic information, the use of omics
approaches to follow up on interesting in vitro or in vivo observa-
tions is very likely going to speed up research progress in the ﬁeld
of probiotics in the near future.
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